. 2021 Nov 16;5(22):4594–4604. doi: 10.1182/bloodadvances.2021005231

Table 2.

Temperature and inflammatory marker analysis at baseline, day 7 and at time of fever

	Diagnosis	Conditioning	Donor, match	Graft	Tmax (°F)	Tmax day after HCT	Fever sample day after HCT	Baseline CXCL9 (RR: ≤ 121 pg/mL)	Day 7 CXCL9	Fever CXCL9	Baseline BAFF (RR: 241-1748 pg/mL)	Day 7 BAFF	Fever BAFF	Baseline sC5b9 (RR: ≤ 244 ng/mL)	Day 7 sC5b9	Fever sC5b9
No graft rejection
Patient 1	FA	Bu/Cy/Flu/ATG	URD, 12/12	T-depleted PBSC	104.7	6	8	<31	<31^*	<31	1547	4708^*	4708	121	141^*	141
Patient 2	FA	Bu/Cy/Flu/ATG	URD, 10/10	T-depleted PBSC	103.1	7	6	<31	33^*	33	1053	5861^*	5861	112	142^*	142
Patient 3	FA	Bu/Cy/Flu/ATG	URD, 8/10	T-depleted PBSC	104.9	6	7	250	44^*	44	2290	6119^*	6119	312	115^*	115
Patient 4	FA	Bu/Cy/Flu/ATG	URD, 10/10	T-depleted PBSC	104.5	4	4	40	85	105	824	6198	5730	90	234	181
Patient 5	FA	Bu/Cy/Flu/ATG	URD, 10/10	T-depleted PBSC	104.5	6	10	32	<31	45	1312	2419	6120	150	N/A	354
Patient 6	FA	Bu/Cy/Flu/ATG	URD, 9/10	T-depleted PBSC	103.3	6	5	<31	45^*	45	2363	4687^*	4687	131	143^*	143
Patient 7	FA	Bu/Cy/Flu/ATG	URD, 10/10	T-depleted PBSC	104.9	6	5	68	33	88	1329	4421	4217	198	288	422
Patient 8	FA	Bu/Cy/Flu/ATG	URD, 10/10	T-depleted PBSC	102.7	7	4	<31	<31^*	<31	1454	3785^*	3785	120	176^*	176
Patient 9	SAA	Bu/Cy/ATG	URD, 9/10	Bone Marrow	103.6	6	7	78	145^*	145	909	5321^*	5321	140	327^*	327
Patient 10	SAA	Flu/Mel	URD, 9/10	PBSC	102.2	5	7	78	70^*	70	990	4274^*	4274	244	288^*	288
Patient 11	SAA	Alem/Flu/Mel	URD, 9/10	T-depleted PBSC	102.6	8	8	56	45^*	45	853	5400^*	5400	143	149^*	149
Patient 12	SAA	Alem/Flu/Mel	URD, 9/10	PBSC	103.3	5	9	233	276^*	276	4500	6816^*	6816	138	182^*	182
Patient 13	SAA	Cy/ATG	Sibling, 10/10	Bone Marrow	101.8	14	16	72	<31	71	719	581	586	251	322	434
Patient 14	SAA	Alem/Flu/Mel	URD, 10/10	T-depleted PBSC	103.3	5	5	<31	39^*	39	736	4560^*	4560	162	134^*	134
Patient 15	SAA	Alem/Flu/Mel	Mother, 10/10	T-depleted PBSC	104.7	4	6	616	59^*	59	4816	5288^*	5288	171	105^*	105
Graft rejection
Patient 16	SAA	Alem/Flu/Mel	URD, 9/10	T-depleted PBSC	105.6	48	48	<31	64	563	545	4364	5362	153	167	336
Patient 17	SAA	Alem/Flu/Mel	URD, 9/10	T-depleted PBSC	103.3	13	13	36	48	530	3179	5240	15 087	125	174	273
Patient 18	SAA	Alem/Flu/Mel	URD, 10/10	T-depleted PBSC	104.2	7	11	74	337	5772	466	8702	2862	141	184	181
Patient 19	SAA	Alem/Flu/Mel	Mother, 7/10	T-depleted PBSC	108.5	11	10	<31	41	6106	2613	8176	16 893	68	141	1070
Patient 20	FA	Bu/Cy/Flu/ATG	Mother, 6/10	T-depleted PBSC	106.9	16	19	52	199	9760	1743	11 494	10 683	81	103	657
Patient 21	FA	Bu/Cy/Flu/ATG	URD, 9/10	T-depleted Bone Marrow	108.1	24	19	80	94	367	1093	3591	8811	105	149	244
Patient 22	GUCFS	Bu/Cy/Flu/ATG	Father, 5/10	T-depleted PBSC	104.9	12	13	36	98	1744	1298	4104	8295	59	60	299

CXCL9 (P = .001), BAFF (P = .002), and sC5b-9 (P = .03) were significantly higher in patients with GR at time of fever compared with febrile controls. Fevers in patients with GR were also significantly higher (P = .002) and occurred significantly later (P = .001) after HCT compared with febrile controls.

Alem, alemtuzumab; ATG, antithymocyte globulin; Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; GUCFS, genetically undefined chromosomal fragility syndrome; Mel, melphalan; N/A, sample was not available for that patient; RR, reference range; URD, unrelated donor.

Fever sample occurred at the same time point as the day 7 sample and they are therefore the same.